CheckMate-901 is a phase 3 open-label clinical research study of drugs named nivolumab and ipilimumab. This study will test these drugs in adults with cancer of the bladder or upper urinary tract (also called urothelial cancer, or UC).
The primary purpose of this study is to test a combination of nivolumab and ipilimumab for UC. Doctors are studying this combination to learn more about its effectiveness compared to the treatment that’s most commonly given for UC.
For more information, visit: https://affinityresearch.com.au/ca209901/